| Year |
Citation |
Score |
| 2024 |
Alahmari AA, Chaubey AH, Jonnakuti VS, Tisdale AA, Schwarz CD, Cornwell AC, Maraszek KE, Paterson EJ, Kim M, Venkat S, Cortes Gomez E, Wang J, Gurova KV, Yalamanchili HK, Feigin ME. CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone mRNA processing. Rna (New York, N.Y.). PMID 38191171 DOI: 10.1261/rna.079931.123 |
0.424 |
|
| 2023 |
Fetisov TI, Borunova AA, Antipova AS, Antoshina EE, Trukhanova LS, Gorkova TG, Zuevskaya SN, Maslov A, Gurova K, Gudkov A, Lesovaya EA, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo. Biomedicines. 11. PMID 36672738 DOI: 10.3390/biomedicines11010230 |
0.324 |
|
| 2022 |
Xiao L, Karsa M, Ronca E, Bongers A, Kosciolek A, El-Ayoubi A, Revalde JL, Seneviratne JA, Cheung BB, Cheung LC, Kotecha RS, Newbold A, Bjelosevic S, Arndt GM, Lock RB, ... ... Gurova KV, et al. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Frontiers in Oncology. 12: 863329. PMID 35677155 DOI: 10.3389/fonc.2022.863329 |
0.319 |
|
| 2022 |
Gurova K. Can aggressive cancers be identified by the "aggressiveness" of their chromatin? Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. e2100212. PMID 35452144 DOI: 10.1002/bies.202100212 |
0.385 |
|
| 2022 |
Goswami I, Sandlesh P, Stablewski A, Toshkov I, Safina AF, Magnitov M, Wang J, Gurova K. FACT maintains nucleosomes during transcription and stem cell viability in adult mice. Embo Reports. e53684. PMID 35179289 DOI: 10.15252/embr.202153684 |
0.347 |
|
| 2021 |
Xiao L, Somers K, Murray JE, Pandher R, Karsa M, Ronca E, Bongers A, Terry R, Ehteda A, Gamble LD, Issaeva N, Leonova KI, O'Connor A, Mayoh C, Venkat P, ... ... Gurova KV, et al. Dual targeting of chromatin stability by the curaxin CBL0137 and histone deacetylase inhibitor panobinostat shows significant preclinical efficacy in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33994371 DOI: 10.1158/1078-0432.CCR-20-2357 |
0.351 |
|
| 2021 |
Ehteda A, Simon S, Franshaw L, Giorgi FM, Liu J, Joshi S, Rouaen JRC, Pang CNI, Pandher R, Mayoh C, Tang Y, Khan A, Ung C, Tolhurst O, Kankean A, ... ... Gurova K, et al. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Cell Reports. 35: 108994. PMID 33852836 DOI: 10.1016/j.celrep.2021.108994 |
0.339 |
|
| 2021 |
Chen M, Brackett CM, Burdelya LG, Punnanitinont A, Patnaik SK, Matsuzaki J, Odunsi AO, Gudkov AV, Singh AK, Repasky EA, Gurova KV. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. Cancer Immunology, Immunotherapy : Cii. PMID 33439292 DOI: 10.1007/s00262-020-02846-8 |
0.324 |
|
| 2020 |
Prendergast L, Hong E, Safina A, Poe D, Gurova K. Histone chaperone FACT is essential to overcome replication stress in mammalian cells. Oncogene. PMID 32533099 DOI: 10.1038/S41388-020-1346-9 |
0.442 |
|
| 2020 |
Sandlesh P, Safina A, Goswami I, Prendergust L, Rosario S, Gomez EC, Wang J, Gurova KV. Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation. Iscience. 23: 101177. PMID 32498018 DOI: 10.1016/j.isci.2020.101177 |
0.39 |
|
| 2020 |
Fedyanin M, Tryakin A, Lisyanskaya AS, Solovyeva E, Fadeeva N, Gladkov O, Moiseyenko V, Cheporov SV, Shpigotskaya P, Purmal A, Miller LL, Leonov A, Zakurdaeva K, Gurova K, Gudkov A, et al. Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors. Journal of Clinical Oncology. 38: 3607-3607. DOI: 10.1200/Jco.2020.38.15_Suppl.3607 |
0.334 |
|
| 2020 |
Sarantopoulos J, Mahalingam D, Sharma N, Iyer RV, Ma WW, Ahluwalia MS, Johnson S, Purmal A, Shpigotskaya P, Hards A, Leonov A, Gurova K, Gudkov A, Zakurdaeva K, Miller LL, et al. Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors. Journal of Clinical Oncology. 38: 3583-3583. DOI: 10.1200/Jco.2020.38.15_Suppl.3583 |
0.348 |
|
| 2020 |
Haber M, Gamble L, Xiao L, Pandher R, Somers K, Murray J, Khan A, Yu D, Franshaw L, Burns MR, Tsoli M, Ehteda A, Cesare A, O’Connor A, Mussai F, ... ... Gurova K, et al. Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Ia13 |
0.416 |
|
| 2019 |
Chang HW, Nizovtseva EV, Razin SV, Formosa T, Gurova KV, Studitsky VM. Histone Chaperone FACT and Curaxins: Effects on Genome Structure and Function. Journal of Cancer Metastasis and Treatment. 5. PMID 31853507 DOI: 10.20517/2394-4722.2019.31 |
0.318 |
|
| 2019 |
Kirsanov KI, Fetisov T, Lesovaya EA, Maksimova V, Trukhanova L, Antoshina E, Gor'kova T, Morozova O, Safina A, Fleyshman D, Salimov R, Shipaeva E, Ivanov R, Leonov A, Purmal AA, ... ... Gurova KV, et al. Prevention of colorectal carcinogenesis by DNA binding small molecule curaxin CBL0137 involves suppression of Wnt signaling. Cancer Prevention Research (Philadelphia, Pa.). PMID 31653646 DOI: 10.1158/1940-6207.Capr-19-0198 |
0.338 |
|
| 2019 |
Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, Wadham C, Middlemiss S, Neznanov N, Kees UR, Lock RB, Gudkov AV, Sutton R, Gurova K, Haber M, et al. Potent anti-leukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. International Journal of Cancer. PMID 31325323 DOI: 10.1002/Ijc.32582 |
0.38 |
|
| 2019 |
Jean MJ, Zhou D, Fiches G, Kong W, Huang H, Purmal A, Gurova K, Santoso NG, Zhu J. Curaxin CBL0137 has the potential to reverse HIV-1 latency. Journal of Medical Virology. PMID 30989696 DOI: 10.1002/Jmv.25487 |
0.303 |
|
| 2019 |
Gurova KV. Chromatin Stability as a Target for Cancer Treatment. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 41: e1800141. PMID 30566250 DOI: 10.1002/bies.201800141 |
0.337 |
|
| 2019 |
Ito MA, Sandlesh P, Goswami I, Prendergast LA, Gurova K. Abstract 5193: Conditional knockout of histone chaperone FACT in mice: Consequences for normal tissues Cancer Research. 79: 5193-5193. DOI: 10.1158/1538-7445.Am2019-5193 |
0.505 |
|
| 2019 |
Nesher E, Safina A, Aljahdali I, Portwood S, Wang E, Wang J, Koman I, Gurova K. Abstract 1755: Chromatin trapping is a key factor for anticancer cytotoxicity of DNA-binding small molecule drugs Cancer Research. 79: 1755-1755. DOI: 10.1158/1538-7445.Am2019-1755 |
0.371 |
|
| 2018 |
Chang HW, Valieva ME, Safina A, Chereji RV, Wang J, Kulaeva OI, Morozov AV, Kirpichnikov MP, Feofanov AV, Gurova KV, Studitsky VM. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins. Science Advances. 4: eaav2131. PMID 30417101 DOI: 10.1126/Sciadv.Aav2131 |
0.335 |
|
| 2018 |
Gurova K, Chang HW, Valieva ME, Sandlesh P, Studitsky VM. Structure and function of the histone chaperone FACT - Resolving FACTual issues. Biochimica Et Biophysica Acta. PMID 30055319 DOI: 10.1016/J.Bbagrm.2018.07.008 |
0.495 |
|
| 2018 |
Sandlesh P, Juang T, Safina A, Higgins MJ, Gurova KV. Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. Plos One. 13: e0199785. PMID 29953487 DOI: 10.1371/journal.pone.0199785 |
0.395 |
|
| 2018 |
Leonova K, Safina A, Nesher E, Sandlesh P, Pratt R, Burkhart C, Lipchick B, Gitlin I, Frangou C, Koman I, Wang J, Kirsanov K, Yakubovskaya MG, Gudkov AV, Gurova K. TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. Elife. 7. PMID 29400649 DOI: 10.7554/Elife.30842 |
0.424 |
|
| 2017 |
Attwood K, Fleyshman D, Prendergast L, Paszkiewicz G, Omilian AR, Bshara W, Gurova K. Prognostic value of histone chaperone FACT subunits expression in breast cancer. Breast Cancer (Dove Medical Press). 9: 301-311. PMID 28496363 DOI: 10.2147/BCTT.S126390 |
0.357 |
|
| 2017 |
Fleyshman D, Prendergast L, Safina A, Paszkiewicz G, Commane M, Morgan K, Attwood K, Gurova K. Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells. Oncotarget. 8: 20525-20542. PMID 28423528 DOI: 10.18632/Oncotarget.15656 |
0.505 |
|
| 2017 |
Safina A, Cheney P, Pal M, Brodsky L, Ivanov A, Kirsanov K, Lesovaya E, Naberezhnov D, Nesher E, Koman I, Wang D, Wang J, Yakubovskaya M, Winkler D, Gurova K. FACT is a sensor of DNA torsional stress in eukaryotic cells. Nucleic Acids Research. PMID 28082391 DOI: 10.1093/Nar/Gkw1366 |
0.331 |
|
| 2017 |
Portwood S, Wang ES, Safina A, Gurova K. Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia Blood. 130: 1372-1372. DOI: 10.1182/Blood.V130.Suppl_1.1372.1372 |
0.365 |
|
| 2016 |
Yacobovich S, Tuchinsky L, Kirby M, Kardash T, Agranyoni O, Nesher E, Redko B, Gellerman G, Tobi D, Gurova K, Koman I, Ashur Fabian O, Pinhasov A. Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: Antitumor activity in mouse melanoma models. Oncotarget. PMID 27556860 DOI: 10.18632/Oncotarget.11363 |
0.403 |
|
| 2016 |
Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Research. PMID 26921329 DOI: 10.1158/0008-5472.Can-15-2162 |
0.458 |
|
| 2016 |
Sharma N, Dermawan J, Purmal A, Lindner D, Wildey G, Dowlati A, Gudkov A, Gurova K, Stark GR. Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma Cancer Research. 76: 3036-3036. DOI: 10.1158/1538-7445.Am2016-3036 |
0.372 |
|
| 2015 |
Fleyshman D, Cheney P, Strose A, Mudambi S, Safina A, Commane M, Purmal A, Morgan K, Wang NJ, Gray J, Spellman PT, Issaeva N, Gurova K. ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin. Cell Cycle (Georgetown, Tex.). 0. PMID 26694952 DOI: 10.1080/15384101.2015.1127478 |
0.414 |
|
| 2015 |
Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, ... ... Gurova KV, et al. Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Science Translational Medicine. 7: 312ra176. PMID 26537256 DOI: 10.1126/Scitranslmed.Aab1803 |
0.393 |
|
| 2015 |
Huang H, Santoso N, Power D, Simpson S, Dieringer M, Miao H, Gurova K, Giam CZ, Elledge S, Zhu J. FACT Proteins, SUPT16H and SSRP1, are Transcriptional Suppressors of HIV-1 and HTLV-1 that Facilitate Viral Latency. The Journal of Biological Chemistry. PMID 26378236 DOI: 10.1074/Jbc.M115.652339 |
0.312 |
|
| 2015 |
Frangou C, Den Haese J, Warunek J, Portwood S, Nowak NJ, Gudkov AV, Gurova K, Wetzler M, Wang ES. Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells Blood. 126: 1391-1391. DOI: 10.1182/Blood.V126.23.1391.1391 |
0.453 |
|
| 2015 |
Haber M, Murray J, Gamble L, Carnegie-Clark A, Webber H, Ruhle M, Henderson MJ, Middlemass S, Carter D, Tsoli M, Ehteda A, Simon S, Oberthuer A, Fischer M, Gurova K, et al. Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting Cancer Research. 75: 1611-1611. DOI: 10.1158/1538-7445.Am2015-1611 |
0.452 |
|
| 2015 |
Dermawan JKT, Hitomi M, Lathia J, Rich J, Gurova K, Stark G, Venere M. STEM-21DISRUPTION OF FACILITATES CHROMATIN TRANSCRIPTION (FACT) SYNERGIZES WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION AND PREFERENTIALLY TARGETS GLIOBLASTOMA STEM CELLS Neuro-Oncology. 17: v212.3-v212. DOI: 10.1093/Neuonc/Nov234.21 |
0.37 |
|
| 2014 |
Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, Toshkov I, Ramachandran R, Martello L, Gurova KV. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget. 5: 11038-53. PMID 25402820 |
0.385 |
|
| 2014 |
Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Molecular Cancer Therapeutics. 13: 2203-14. PMID 25028470 DOI: 10.1158/1535-7163.Mct-14-0013 |
0.462 |
|
| 2014 |
Burkhart C, Kohrn R, Walker B, Gurova K, Purmal A, Gudkov A. Abstract 815: CBL0137 demonstrates significant antitumor activity against hepatocellular carcinoma alone and in combination with sorafenib Cancer Research. 74: 815-815. DOI: 10.1158/1538-7445.Am2014-815 |
0.432 |
|
| 2014 |
Burkhart C, Kohrn R, Walker B, Meyer D, Gurova K, Gudkov A. Abstract 800: Synergistic effects of CBL0137 and gemcitabine against non-small cell lung and pancreatic cancer xenografts Cancer Research. 74: 800-800. DOI: 10.1158/1538-7445.Am2014-800 |
0.494 |
|
| 2013 |
Safina A, Garcia H, Commane M, Guryanova O, Degan S, Kolesnikova K, Gurova KV. Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells. Cell Cycle (Georgetown, Tex.). 12: 2423-34. PMID 23839038 DOI: 10.4161/Cc.25452 |
0.59 |
|
| 2013 |
Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, ... ... Gurova KV, et al. Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers. Cell Reports. 4: 159-73. PMID 23831030 DOI: 10.1016/J.Celrep.2013.06.013 |
0.652 |
|
| 2013 |
Dermawan JKT, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark G. Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A263 |
0.434 |
|
| 2012 |
Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV, Gurova KV. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prevention Research (Philadelphia, Pa.). 5: 1025-35. PMID 22689915 DOI: 10.1158/1940-6207.Capr-11-0529 |
0.387 |
|
| 2011 |
Garcia H, Fleyshman D, Kolesnikova K, Safina A, Commane M, Paszkiewicz G, Omelian A, Morrison C, Gurova K. Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells Oncotarget. 2: 783-796. PMID 21998152 DOI: 10.18632/Oncotarget.340 |
0.646 |
|
| 2011 |
Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, ... ... Gurova KV, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Science Translational Medicine. 3: 95ra74. PMID 21832239 DOI: 10.1126/Scitranslmed.3002530 |
0.32 |
|
| 2010 |
Gurova K, Gudkov AV. Abstract SY18-02: Targeting transcriptional regulators for simultaneous modulation of p53 and NF-κB in cancer treatment Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Sy18-02 |
0.46 |
|
| 2009 |
Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents. Future Oncology (London, England). 5: 1685-704. PMID 20001804 DOI: 10.2217/Fon.09.127 |
0.364 |
|
| 2009 |
Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (Georgetown, Tex.). 8: 3960-70. PMID 19901558 DOI: 10.4161/Cc.8.23.10179 |
0.323 |
|
| 2006 |
Isachenko N, Dyakova N, Aushev V, Chepurnych T, Gurova K, Tatosyan A. High expression of shMDG1 gene is associated with low metastatic potential of tumor cells Oncogene. 25: 317-322. PMID 16205647 DOI: 10.1038/sj.onc.1209022 |
0.309 |
|
| 2002 |
Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA, Gudkov AV. Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biology & Therapy. 1: 39-44. PMID 12170763 DOI: 10.4161/Cbt.1.1.39 |
0.305 |
|
| 2002 |
Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene. 21: 3532-40. PMID 12032855 DOI: 10.1038/Sj.Onc.1205438 |
0.376 |
|
| Show low-probability matches. |